Skip to main content
Equibles

Carrie Brownstein

Cellectis S.A. (CLLS)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Carrie Brownstein

Earlier roles on record: Board Member at Shattuck Labs, Inc. (STTK) until August 25, 2025. Shattuck Labs, Inc. reported in an 8-K filed August 26, 2025 that Carrie Brownstein resigned as Class I director, effective August 25, 2025. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed January 25, 2024 that Carrie Brownstein resigned as Chief Medical Officer, effective January 19, 2024. The proxy statement of Zentalis Pharmaceuticals, Inc. reports total compensation of $8,830,657 for Carrie Brownstein in fiscal 2022, including a base salary of $127,500.

“Effective on the Closing Date, Tyler Brous, a Class I director, Dr. Carrie Brownstein, a Class I director, Michael Lee, a Class I director, and Dr. Kate Sasser, a Class II director, resigned from the Board of Directors (the "Board") of the Company as well as any respective committees of the Board of which they were members.”
Shattuck Labs, Inc. Form 8-K, filed August 26, 2025 · Read the filing
“On and effective as of the Transition Date, Dr. Brownstein stepped down for personal reasons.”
Zentalis Pharmaceuticals, Inc. Form 8-K, filed January 25, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Zentalis Pharmaceuticals, Inc. (ZNTL) $127,500 $8,830,657

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.